Circulating Biomarkers of Vulnerable Atheromatous Plaques
Pp. 3-21 (19)
Rupture of atherosclerotic plaques is a major cause of cardiovascular events,
including acute coronary syndromes, myocardial infarction and stroke. Identification of
the vulnerable plaques is one of the most important steps leading to the treatment of
patients with the disease. In spite of a considerable effort in identifying patients with
vulnerable plaque, including the use of both circulatory and imaging biomarkers to
delineate the molecular, cellular, and structural components and/or evolution of
atherosclerosis and plaque vulnerability, it still lacks of such a specific biomarker for
this disease. This review will focus on recent advances on discovery of circulating
markers in atherosclerosis and hope that some of these markers might be of values to
assess vulnerable atheromatous plaques. It is hoped that these biomarkers may be able
to facilitate disease diagnosis and the development of new therapeutics to treat
vulnerable plaque and its consequence of cardiovascular diseases.
Atherosclerosis, atherosclerotic plaque, biomarker, cardiovascular
disease, circulatory biomarker, inflammation, plaque rupture, translational
medicine, vulnerable plaque.
Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.